Ra Capital Management, L.P. Purchases 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The stock was acquired at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company’s stock, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 5th, Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock. The stock was acquired at an average price of $30.64 per share, with a total value of $10,470,974.88.

Janux Therapeutics Trading Down 0.4 %

Shares of JANX stock opened at $30.64 on Friday. Janux Therapeutics, Inc. has a 1 year low of $29.63 and a 1 year high of $71.71. The firm’s fifty day simple moving average is $41.27 and its 200 day simple moving average is $47.48. The firm has a market capitalization of $1.81 billion, a P/E ratio of -26.19 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Leerink Partners lifted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Stifel Nicolaus lifted their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Wedbush reissued an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $88.00.

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Plato Investment Management Ltd increased its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the period. Russell Investments Group Ltd. increased its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics in the 4th quarter valued at $59,000. Avanza Fonder AB bought a new stake in Janux Therapeutics in the 4th quarter valued at $139,000. Finally, Meeder Asset Management Inc. bought a new stake in Janux Therapeutics in the 4th quarter valued at $159,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.